SAB Historical Balance Sheet
| SABS Stock | USD 3.85 0.40 9.41% |
Trend analysis of SAB Biotherapeutics balance sheet accounts such as Total Stockholder Equity of 36 M, Net Tangible Assets of 29.2 M, Property Plant And Equipment Net of 25.2 M or Accounts Payable of 898.6 K provides information on SAB Biotherapeutics' total assets, liabilities, and equity, which is the actual value of SAB Biotherapeutics to its prevalent stockholders. By breaking down trends over time using SAB Biotherapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining SAB Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether SAB Biotherapeutics is a good buy for the upcoming year.
SAB |
About SAB Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of SAB Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. SAB Biotherapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of SAB Biotherapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which SAB currently owns. An asset can also be divided into two categories, current and non-current.
SAB Biotherapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of SAB Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in SAB Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on SAB Biotherapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of SAB Biotherapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Retained Earnings Total Equity
The portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt.Most accounts from SAB Biotherapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into SAB Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.At this time, SAB Biotherapeutics' Other Current Assets are comparatively stable compared to the past year. Total Liabilities is likely to gain to about 27.5 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 5.5 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 6.7M | 5.9M | 5.9M | 5.5M | Total Assets | 79.4M | 50.9M | 83.9M | 63.5M |
SAB Biotherapeutics balance sheet Correlations
Click cells to compare fundamentals
SAB Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.